Peregrine Asset Advisers’s Biogen BIIB Stock Holding History

Peregrine Asset Advisers’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-923	Closed	-$214K	–	185
2024 Q2	$214K	Buy	+923	New	+$201K	0.08%	154
2024 Q1	–	Sell	-923	Closed	-$239K	–	174
2023 Q4	$239K	Hold	923	–	–	0.12%	137
2023 Q3	$237K	Buy	+923	New	+$247K	0.12%	130
2020 Q3	–	Sell	-1,596	Closed	-$427K	–	98
2020 Q2	$427K	Hold	1,596	–	–	0.24%	62
2020 Q1	$505K	Sell	1,596 -100	-6%	-$30.3K	0.38%	47
2019 Q4	$503K	Buy	+1,696	New	+$471K	0.12%	63
2019 Q3	–	Sell	-20,670	Closed	-$4.83M	–	102
2019 Q2	$4.83M	Buy	+20,670	New	+$4.77M	2.51%	11
2015 Q3	–	Sell	-3,100	Closed	-$1.25M	–	91
2015 Q2	$1.25M	Hold	3,100	–	–	0.94%	25
2015 Q1	$1.31M	Hold	3,100	–	–	0.86%	33
2014 Q4	$1.05M	Hold	3,100	–	–	0.74%	38
2014 Q3	$1.03M	Hold	3,100	–	–	0.84%	37
2014 Q2	$977K	Hold	3,100	–	–	0.88%	33
2014 Q1	$948K	Hold	3,100	–	–	0.73%	42
2013 Q4	$867K	Hold	3,100	–	–	0.76%	32
2013 Q3	$746K	Hold	3,100	–	–	0.72%	32
2013 Q2	$667K	Buy	+3,100	New	+$662K	0.69%	35

Other funds holding BIIB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Peregrine Asset Advisers's BIIB Position: Q3 2024 in Review

Peregrine Asset Advisers sold out of Biogen (BIIB) in Q3 2024, closing a stake of 923 shares — an estimated $214K sold.

Peregrine Asset Advisers first reported a position in BIIB in Q2 2013 and held it in 16 quarters. The position peaked at $4.83M in Q2 2019. 917 funds tracked by Wall St. Rank hold BIIB as of Q3 2024.

Peregrine Asset Advisers reported no remaining Biogen position as of Q3 2024 after selling out during the quarter.
Peregrine Asset Advisers sold 923 Biogen shares in Q3 2024, an estimated $214K.
Peregrine Asset Advisers first reported a position in Biogen in Q2 2013 and held it in 16 quarters.
Peregrine Asset Advisers's Biogen position peaked at $4.83M in Q2 2019.
917 funds tracked by Wall St. Rank held Biogen as of Q3 2024.

Based on Peregrine Asset Advisers's 13F filing for Q3 2024, filed 4 Nov 2024.